Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma

• This review is to focus on the application of BCLC and HKLC staging systems in guiding decision making for HBV-related HCC.
• The respective advantages and disadvantages of BCLC and HKLC staging systems are deeply elucidated in this review.
• If improved in the future, HKLC system will become the new standard and be accepted universally especially in Asian countries.

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related death worldwide. HCC incidence has increased over the last few years, with more than half of HCC cases being reported in China, where hepatitis B virus (HBV) infection is the main etiologic factor. The heterogeneity in HCC's worldwide distribution and the differences in its etiology in different locations may result in prognosis estimation and therapeutic decision making being more complicated for HCC patients. In the past decade, several clinical staging systems have been developed based on relevant prognostic factors. Among them, the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) staging systems are the only two classification systems that link prognostic classification to treatment indications. In this review, we mainly focus on the use of the BCLC and HKLC staging systems for guiding therapeutic decision making for HCC, the respective advantages and disadvantages of each classification system, and future perspectives for the improvement of the HKLC model.